From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves ...

Shares of AngioDynamics (ANGO) have gained 26.5% over the past four weeks to close the last trading session at $7.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.33 indicates a potential upside of 74.3%.The average comprises three short-term price targets ranging from a low of $13 to a high of $14, with a standard deviation of $0.58. While the lowest estimate indicates a ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Kronos Worldwide, Inc. (KRO) : This titanium dioxide pigment company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.9% over the last 60 days.First United Corporation (FUNC) : This bank holding company for First United Bank & Trust has seen the Zacks Consensus Estimate for its current year earnings increasing 9.1% over the last 60 days.PROG Holdings, Inc. (PRG) : This financial technology holding compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------- ...

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 6 cents for fourth-quarter fiscal 2024, against the year-ago quarter’s adjusted earnings per share (EPS) of 2 cents per share. However, the metric was narrower than the Zacks Consensus Estimate of a loss of 20 cents per share.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC, Midline, and tip location product portfolios and the discontinued RadioFrequency and Syntrax support catheter products), adjusted loss ...

Loading...Loading...Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro.Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales ...

AngioDynamics Inc. (NASDAQ:ANGO) Q4 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steve Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics fiscal year 2024 Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentatio ...

AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 16, 2024 Forward-Looking Statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunitie ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 70%. A quarter ago, it was expected that this medical device maker would post a loss of $0.14 per share when it actually produced a loss of $0.16, delivering a surprise of -14.29%.Over the last four quarters, the company ...

Exhibit 99.1 /namics PRESS RELEASE Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patient ...